Second-line therapy for Non-small Cell Lung Cancer (NSCLC):EGFR T790M mutation-positive, locally advanced or metastatic NSCLC
First-line therapy for Non-small Cell Lung Cancer (NSCLC):EGFR mutation-positive, locally advanced or metastatic NSCLC
Postoperative adjuvant therapy of NSCLC:Postoperative adjuvant therapy for patients with EGFR mutation-positive NSCLC at phase 1I-IIIa
Second-line therapy for NSCLC:Applicable to advanced NSCLC with EGFR ex20ins mutation
First-line therapy for NSCLC:Applicable to advanced NSCLC with EGFR ex20ins mutation